Soleno Therapeutics Inc (SLNO)
EBITDA Growth
155.86%
TTM · Period ending:
SLNO EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported155.86%period ending
Latest reported155.86%period ending
SLNO TTM EBITDA YoY % (-480.45% → 155.86%)
Year-over-year change
High-resolution chart · PNG
SLNO ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 155.8569% | |
| 116.6392% | |
| 50.3091% | |
| -172.6083% | |
| -283.6183% | |
| -364.641% | |
| -343.3911% | |
| -136.5442% | |
| -102.3009% | |
| -58.6174% | |
| -29.3951% | |
| -7.8141% | |
| 7.8227% | |
| 23.6038% | |
| 26.8286% | |
| 20.0623% | |
| 14.8187% | |
| -1.0035% | |
| -9.3991% | |
| -10.9022% | |
| -24.9354% | |
| -41.226% | |
| -108.0481% | |
| -143.9145% | |
| -163.5354% | |
| -171.5637% | |
| -28.9685% | |
| -16.9698% | |
| -1.9212% | |
| 3.0615% | |
| -27.4396% | |
| -19.2218% | |
| -17.0049% | |
| 26.6303% | |
| 28.5907% | |
| 37.4599% | |
| 42.6264% | |
| 9.3048% | |
| -13.2833% | |
| -53.5924% | |
| -103.2933% | |
| -136.2895% | |
| -166.0735% | |
| -136.1984% | |
| -94.4528% | |
| -480.4487% |